Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 165-171

  Omura, G A ^a   Blessing, J A ^a   Vaccarello, L ^a   Berman, M L ^a   Clarke Pearson, D L ^a   Mutch, D G ^a   Anderson, B ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IFOSFAMIDE; MESNA; MITOLACTOL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

EID: 0031023552     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.165     Document Type: Article

References (25)

1. Omura GA: Chemotherapy for cervix cancer. Semin Oncol 21:54-62, 1994
2. Bonomi P, Blessing JA, Stehman FB, et al: Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 3:1079-1085, 1985
3. Stehman FB, Blom J, Blessing JA, et al: Phase II trial of galactitol 1,2:5,6-dianhydro (NSC #132313) in the treatment of advanced gynecologic malignancies: A Gynecologic Oncology Group study. Gynecol Oncol 15:381-390, 1983
4. Lira-Puerto VB, Morales-Canfield F, Wernz J, et al: Activity of mitolactol in cancer of the uterine cervix. Cancer Treat Rep 68:669-670, 1984
5. Stehman FB, Blessing JA, McGehee R, et al: A phase II evaluation of mitolactol (NSC #104800) in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 7:1892-1895, 1989
6. Vogl SE, Seltzer V, Camacho A: Dianhydrogalactitol and cisplatin in combinations for advanced cancer of the uterine cervix. Cancer Treat Rep 66:1809-1812, 1982
7. Omura GE, Hubbard JL, Hatch KD, et al: Chemotherapy of cervix cancer with mitolactol (dibromodulcitol, NSC 104800) and cisplatin: A phase I study of the Gynecologic Oncology Group. Am J Clin Oncol 15:185-187, 1992
8. Buxton EJ, Meanwell CA, Hilton C, et al: Combination bleomycin, ifosfamide and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 81:359-361, 1989
9. Blessing JA: Design, analysis and interpretation of chemotherapy trials in gynecologic cancer, in Deppe G (ed): Chemotherapy of Gynecologic Cancer (ed 2). New York, NY, Liss, 1990, pp 63-97
10. Cox DR: The Analysis of Binary Data. London, United Kingdom, Chapman & Hall, 1977
11. Cox DR: Regression model and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
12. Hollander M, Wolf DA: Nonparametric Statistical Methods. New York, NY Wiley, 1973
13. Meanwell CA, Blake AE, Kelly KA, et al: Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer 22:815-919, 1986
14. Baker LH, Opipari MI, Wilson H, et al: Mitomycin C, vincristine, and bleomycin therapy for advanced cervical cancer. Obstet Gynecol 52:146-150, 1978
15. Edmonson JH: Phase II studies of bleomycin, cyclophosphamide, doxorubicin and cisplatin, and bleomycin and cisplatin in advanced cervical carcinoma. Am J Clin Oncol 11:149-151, 1988
16. Baker L, Boutselis J, Alberts D, et al: Combination chemotherapy for patients with disseminated carcinoma of the uterine cervix. Proc Am Soc Clin Oncol 4:120, 1985 (abstr)
17. Alberts DS: Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix. J Clin Oncol 5:1791-1795, 1987
18. Greenberg BR, Kardinal CG, Pajak TF, et al: Adriamycin versus Adriamycin and bleomycin in advanced epidermoid carcinoma of the cervix. Cancer Treat Rep 61:1383-1384, 1977
19. Bennett JM, Troxel AB, Gelman R, et al: Myelodysplastic syndrome and acute myeloid leukemia secondary to mitolactol treatment in patients with breast cancer. J Clin Oncol 12:874-875, 1994
20. Wallace HJ, Jr, Hreshchyshyn MM, Wilbanks GD, et al: Comparison of the therapeutic effects of Adriamycin alone versus Adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep 62:1435-1441, 1978
21. Thigpen JT, Blessing JA, DiSaia PJ, et al: A randomized comparison of a rapid versus prolonged (24 hour) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol Oncol 32:198-202, 1989
22. McGuire WP III, Arseneau J, Blessing JA, et al: A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol 7:1462-1468, 1989
23. Bezwoda WR, Missenbaum M, Derman DP: Treatment of metastatic and recurrent cervix cancer with chemotherapy - A randomized trial comparing hydroxyurea and cisdiamminedichloro-platinum plus methotrexate. Med Pediatr Oncol 14:17-19, 1986
24. Long HJ, Cross WG, Wieand HS, et al: Phase II trial of methotrexate, vinblastine, doxorubicin and cisplatin in advanced/ recurrent cancer of the uterine cervix and vagina. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Gynecol Oncol 57:235-239, 1995
25. Murad AM, Medina L, Andrade CA, et al: Phase II open label multicentric trial of MVAC - methotrexate (M), vinblastine (V), doxorubicin (D) and cisplatin (C) plus granulocyte colony stimulating factor (FILGRASTIM) in advanced recurrent cervical carcinoma: Final report. Proc Am Soc Clin Oncol 14:276, 1995 (abstr)